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Data presented in this Data in Brief article correspond to the
article "in vivo" silencing of CD40 reduces progression of
experimental atherogenesis through a NFκB/miR-125b axis and
reveals new potential mediators in the pathogenesis of ather-
osclerosis" (M. Hueso, L. De Ramon, E. Navarro, E. Ripoll, J.M.
Cruzado, J.M. Grinyo, J. Torras, 2016) [1]. Here, we describe the
validation of the silencing of CD40 expression with a speciﬁc
siRNA in ApoE/ mouse aortas, and its systemic effects on
splenic lymphocytic subpopulations as well as on the inﬁltra-
tion of aortic intima by F4/80þ , galectin-3þ macrophages or by
NF-κBþ cells. We also show the output of a Gene Ontology and
TLDA analysis which allowed the detection of potential med-
iators of atherosclerosis progression. We provide the scientiﬁc













M. Hueso et al. / Data in Brief 9 (2016) 1105–11121106during atherosclerosis progression but downregulated upon
CD40 silencing.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Molecular Biology
ore speciﬁc
subject areaCardiovascular gene expressionype of data Tables and Figures
ow data was
acquiredBy ﬂow cytometry, immunohistochemistry, microarray proﬁling, Taqman low
density array proﬁlingata format Analyzed
xperimental
factorsApoE / intraperitoneally-treated with an anti-CD40 speciﬁc siRNAxperimental
featuresExpression of mRNAs/miRNAs in the ascending aorta of ApoE / was com-
pared with that of mice treated with a scrambled siRNA as controlata source
locationn.aata accessibility Data are available with this articleValue of the Data
1. CD40 was silenced "in vivo" with a speciﬁc siRNA in ApoE / mice. Silencing was conﬁrmed by
measuring CD40 expression by qPCR, IHC and ﬂow-cytometry.
2. Inﬁltrating macrophages were detected in atherosclerotic aortas of ApoE / mice and its number
decreased upon CD40 silencing.
3. Gene Ontology (GO) analysis targeted a number of components of the NF-kB pathway, as well as
members of the Clec/Klr gene families as potentially involved in disease progression. Furthermore,
TLDA proﬁling detected a number of murine miRNAs also potentially involved in disease
progression.
4. This data provide evidences of the potency of the speciﬁc siRNA used.1. Data
The dataset of this article provides information on the validation of the silencing of the CD40 gene
in the aorta from ApoE-deﬁcient mice upon treatment with a speciﬁc siCD40 [Fig. 1], the description
of their systemic effects in spleen cell subpopulations [Table 1], and the quantiﬁcation of the inﬁl-
tration of macrophages and of NF-κBþ cells in their aortic plaques [Fig. 2]. We also present a Gene
Ontology (GO) analysis [Fig. 3], centered in components of the NF-κB pathway [Table 2], or in the Clec
and Klr families [Table 3], as well as a miRNA gene expression data analysis [Table 4] during disease
progression and upon siCD40 treatment. Finally we present the demographic data for the patients
included in the accompanying study [Table 5].
Table 1
Immunophenotype data analysis of spleen cell sub-populations from CD40-silenced in ApoE-deﬁcient mice.
B/8w SC/24w siCD40/24w p
n 5 4 8
CD3þ 1776% 2878% 3372% 0.044
CD3þCD40þ 1776% 16710% 772%* 0.008
CD4þ /CD8þ 1.870.5% 2.771.1% 3.271.2% 0.040
CD19þ 4877% 2974% 1979% 0.005
CD19þCD40þ 4576% 2874% 20714% 0.01
CD11bþ 1272% 13711% 974% 0.32
CD11bþCD40þ 1872% 3174% 1876%* 0.029
CD11bþCD86þCD40þ 572% 471% 371% 0.15
CD11bþCD206þCD40þ 472% 270.4% 272% 0.08
CD11cþCD40þ 772% 871% 672% 0.39
Fig. 1. Efﬁciency of CD40 expression silencing with the siCD40. (A). Dot plot of CD40 expression in the aortas of ApoE / mice
at basal conditions (B/8w), or treated with the anti-CD40 siRNA (siCD40) or with the SC control siRNA (SC). Mean is represented
by a line. (B). Box plot quantifying CD40þ cells in ascending aortas of mice treated with siCD40 (n¼12 mice) or SC (n¼7). (C).
Representative staining of CD40þ cells in the aortic sinus (arrows). Scale bars are 100 mm. Kruskall–Wallis test.
M. Hueso et al. / Data in Brief 9 (2016) 1105–1112 11072. Experimental design, materials and methods
2.1. Study design
CD40 was silenced with a speciﬁc siRNA (siCD40) in ApoE / mice. Global patterns of expression
of mRNAs/miRNAs in the ascending aorta were compared among siCD40 and SC-control treated mice.
Fig. 2. CD40 silencing results in a reduced macrophage inﬁltration and NF-κBþcells in plaques ofApoE /mice treated with
siCD40. (A). Representative images of F4/80, galectin-3 or NF-κB staining at 24w. In all cases, arrows show positive cells for the
stated antigen. (B). Box plot quantifying neointimal macrophages (as F4/80þ or galectin-3þ cells) and NF-κBþ cells in
ascending aortas of mice treated with siCD40 (n¼8 mice), SC (n¼3) and Veh (n¼4) at 24w. Scale bars are 100 mm. Kruskall–
Wallis test.
M. Hueso et al. / Data in Brief 9 (2016) 1105–111211082.2. Validation of CD40 silencing efﬁciency
CD40-silencing was validated by qPCR and IHC (Fig. 1). Sections were evaluated by hematoxylin/
eosin staining and antigen-speciﬁc IHC using standard procedures.2.3. Analysis of macrophage cell inﬁltration in plaques of ApoE-deﬁcient mice treated with siCD40
F4/80þ , galectin-3þ , and NF-kBþ cells were detected and quantiﬁed by antigen-speciﬁc IHC using
standard procedures (Fig. 2).
Fig. 3. GO charts for genes down-regulated in the stated experiments. Every pie portion stands for a functional group of genes
and its size is proportional to the number of genes that belong to that group.
M. Hueso et al. / Data in Brief 9 (2016) 1105–1112 11092.4. Evaluation of the systemic effect of CD40 silencing
Changes in splenic lymphoid cell subsets were characterizaed by using a BD FACS Canto II Cytometer
after double or triple staining with monoclonal antibodies (Table 1). Splenocytes were isolated as pre-
viously described [2] and incubated with anti-CD19APC (clone 1D3), anti-CD3APC (clone 145-2C11), anti-
CD4PECY7 (clone RM4-5), anti-CD8PERCP-CY5.5 (clone 53-6.7), anti-CD11cPE (clone HL3), anti-CD11bAPC-CY7
Table 2
Gene Ontology data analysis (GO¼Biological process/Immune system process/Immune response) centered on the genes
encoding components of the NF-κB pathway.






log2FC -log10(PVal) log2FC -log10(PVal) log2FC -log10(PVal) log2FC -log10(PVal) log2FC -log10(PVal)
IKKA-
CHUK
1.13 1.83 n.s. n.s. n.s. n.s. 1.09 1.50 n.s. n.s.
IKKB 3.31 3.05 2.79 2.75 n.s. n.s. n.s. n.s. 1.29 1.72
IKKE1 n.s. n.s. n.s. n.s. n.s. n.s. 1.16 3.28 n.s. n.s.
SIKE n.s. n.s. n.s. n.s. 2.05 3.38 n.s. n.s. n.s. n.s.
IKBA n.s. n.s. n.s. n.s. 2.33 2.05 n.s. n.s. n.s. n.s.
Table 3
Gene Ontology data analysis (GO¼Biological process/Immune system process/Immune response) centered on the genes
encoding components of the Clec and Klr families.
Gene SC/10w vs. B/8w UP SC/10w vs. B/8w DOWN SC/24w vs. B/8w UP SC/24w vs. B/8w DOWN
log2FC  log10(PVal) log2FC  log10(PVal) log2FC  log10(PVal) log2FC  log10(PVal)
Clec1a n.s. n.s. n.s. n.s. 1.90 3.07 n.s. n.s.
Clec2e n.s. n.s. n.s. n.s. 1.90 1.69 n.s. n.s.
Clec2g n.s. n.s. n.s. n.s. 3.86 1.62 n.s. n.s.
Clec2i n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Clec4a2n n.s. n.s. n.s. n.s. 1.04 2.64 n.s. n.s.
Clec4a2nn 1.47 5.57 n.s. n.s. 1.01 1.91 n.s. n.s.
Clec4d n.s. n.s. 1.20 1.37 n.s. n.s. n.s. n.s.
Clec4e n.s. n.s. n.s. n.s. 1.37 2.50 n.s. n.s.
Clec4f n.s. n.s. n.s. n.s. 2.02 2.10 n.s. n.s.
Clec11a n.s. n.s. n.s. n.s. 2.23 1.82 n.s. n.s.
Clec18a 2.42 3.42 n.s. n.s. n.s. n.s. n.s. n.s.
D21Riknnn n.s. n.s. n.s. n.s. 3.06 1.40 n.s. n.s.
Klra1 n.s. n.s. n.s. n.s. 3.01 1.41 n.s. n.s.
Klra2 n.s. n.s. n.s. n.s. 1.41 2.20 n.s. n.s.
Klra9 1.02 1.64 n.s. n.s. n.s. n.s. n.s. n.s.
Klra18 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Klra21 n.s. n.s. n.s. n.s. n.s. n.s. 2.01 1.37
Klrb1a n.s. n.s. n.s. n.s. 1.66 1.30 n.s. n.s.
Klrc2 n.s. n.s. 1.10 1.62 n.s. n.s. n.s. n.s.
Klre1 n.s. n.s. n.s. n.s. 1.39 1.65 n.s. n.s.
Klri2 n.s. n.s. 1.47 1.85 n.s. n.s. n.s. n.s.
n Clec4a2 Transcript variant 2.
nn Clec4a2 Transcript variant 3.
nnn D21Rik stands for RIKEN cDNA 4922502D21, also known as Clec2m.
M. Hueso et al. / Data in Brief 9 (2016) 1105–11121110(cloneM1/70), anti-F4/80PE (clone BM8), antiCD40FITC (clone HM40-3), anti-CD86FITC (Clone GL1), and
anti-CD206FITC (clone C068C2), all from BD Biosciences (BD Biosciences, San Jose, CA, USA). For each
marker, results are expressed as percentage of the total number of cells acquired. Kruskal–Wallis test.
*po0.05 by Bonferroni test to compare SC/24w vs siCD40/24w.2.5. Gene Ontology (GO) analysis
RNA extraction, microarray hybridization and analysis were performed on a commercial basis at
Arraystar Inc. (Rockville, MD, USA). Differentially expressed mRNAs were identiﬁed in Volcano plots
by using the standard thresholds of log2 (Fold Change)41 and  log10 (P-Value)41.30 [1]. The Gene
Table 4
TLDA data analysis of miRNA expression.
miRNA SC/24w vs. B/8w siCD40/24w vs. SC/24w
log2FC  log10(PVal) log2FC  log10(PVal)
miR-let7i 2,96 1,79 0,71 0,53
miR-10a 4,77 2,69 0,26 0,08
miR-26a 2,51 1,82 1,28 1,30
miR-27a 1,53 1,85 0,64 0,52
miR-27b 4,69 1,49 0,83 0,69
miR-30a 2,35 2,69 1,15 1,34
miR-122 6,28 1,35 0,99 1,07
miR-125b-5p 4,29 2,39 1,73 2,52
miR-130a 4,10 1,60 1,15 0,88
miR-132 0,15 0,22 0,51 0,63
miR-324-5p 4,25 1,45 1,68 0,86
miR-363 N.D. N.D. 2,55 2,39
miR-465a-5p 1,88 1,52 N.D. N.D.
miR-491 2,29 1,69 0,41 0,34
miR-543 4,43 1,60 0,47 0,33
Table 5
Clinical characteristics of patients from which aortic tissue (advanced plaque and normal aorta) was extracted.
ID Age Gender Cause of death Diabetes Hypertension Dyslipidemia
4 60 Female Cardiovascular No Yes No
5 83 Female Cardiovascular No Yes No
12 60 Female Cardiovascular Yes Yes Yes
21 76 Male Infection Yes Yes No
136 68 Female Cancer No No No
149 86 Female Cardiovascular No Yes No
ID: Our identiﬁcation Number.
M. Hueso et al. / Data in Brief 9 (2016) 1105–1112 1111Ontology (GO) analysis (www.pantherdb.org) [3–5] was used to classify differentially expressed
mRNAs by their functional roles. Genes which passed the volcano plot thresholds were arranged in
pie charts (Fig. 3) and then classiﬁed in “GO Biological process” categories. Transcripts belonging to
the “Immune System Process” category (level 1, GO:0002376) were subsequently studied (Level
0¼Biological process, Level 1¼ Immune system process, (GO:0002376), and Level 2¼ Immune
Response (GO:0006955) [6]. Every pie portion stands for a functional group of genes and its size is
proportional to the number of genes that belong to that group. Shown are genes of the NF-kB
pathway (Table 2), and of the Clec/Klr family (Table 3).2.6. Gene expression miRNA proﬁling of mouse aortas using TLDA cards
Total RNA from frozen aortic samples was studied by TLDA cards. MiRNA expression data from the
TLDAs were analyzed with the ExpressionSuite Software v1.0.3 (Life Technologies) by using the ΔΔCt
method after global normalization [7]. Differentially expressed miRNAs were identiﬁed in “Volcano
plots. Expression changes are shown as log2 Fold Change (log2FC) after comparing normalized
expression for each experiment. Gene name (Gene), changes in expression (log2 FC), and the statis-
tical signiﬁcance of the replicates ( log10 (PVal) are shown. In all cases the thresholds used were:
log2 FC41 and  log10 (PVal) 41.30. n.s.¼either log2FC or  log10 (PVal) were below the thresholds.
Table 4 shows the most signiﬁcant hits found.
M. Hueso et al. / Data in Brief 9 (2016) 1105–111211122.7. Demographics of human samples
Abdominal human aortas were collected from autopsy material from patients deceased in the HUB
from November/2009-February/2010. Conﬁdentiality was protected following national guidelines.
The study was performed conform the declaration of Helsinki and approved by the Clinical Research
Ethics Committee of HUB (PR163/13). Demographics of the patients involved in the study are shown
in Table 5.Acknowledgments
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